An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.

对新型抗菌药物治疗由多重耐药细菌病原体全球传播引起的危及生命的感染的需求不断增加，这与目前对其开发的投资水平形成鲜明对比，特别是在天然产品衍生和合成小分子。全世界迫切需要展示创新化学和作用模式的新药物来应对抗菌素耐药性带来的公共卫生威胁。在这里，我们的联盟提出了一个战略蓝图，以大幅提高我们发现和开发新抗生素的能力。我们提出短期和长期解决方案，以克服研究和资助各个部门最紧迫的局限性，旨在弥合学术、工业和政治利益相关者之间的差距，